文献速递基础与转化研究流行病学与生物统计组学、生物样本库与精准医学

SNP芯片检测罕见致病变异的可靠性:基于人群的回顾性诊断评估

Use of SNP chips to detect rare pathogenic variants: retrospective, population based diagnostic evaluation.
PubMed 文献 · BMJ · 2021-02-15

常见变异检测性能良好,但极罕见变异阳性预测值极低,BRCA1/2致病变异灵敏度仅34.6%、阳性预测值4.2%。结论认为SNP芯片极不可靠,不应在无验证情况下指导健康决策。

要点

  • SNP芯片对常见变异检测灵敏度、特异度等均高于99%。
  • 极罕见变异(频率低于0.001%)阳性预测值极低,仅16%杂合基因型被测序确认。
  • BRCA1/2致病变异芯片检测灵敏度34.6%、阳性预测值4.2%,不应直接用于健康决策。

核心结论

  • SNP芯片对极罕见致病变异基因分型极不可靠,无验证不应指导健康决策。

主要发现

  • 频率低于0.001%的极罕见变异,4757个杂合基因型仅16%被测序确认。
  • 21名消费者数据共享者中20人至少有一个假阳性罕见致病变异。
  • BRCA1/2致病变异芯片检测灵敏度34.6%、特异度98.3%、阳性预测值4.2%、阴性预测值99.9%。
  • 芯片阳性者BRCA相关癌症风险与年龄匹配对照相似(比值比1.31,95%CI 0.99-1.71),测序阳性者风险显著升高(比值比4.05,95%CI 2.72-6.03)。

关键数值与推荐

  • 极罕见变异(频率低于0.001%)杂合基因型测序确认率仅16%。
  • BRCA1/2致病变异芯片检测灵敏度34.6%、特异度98.3%、阳性预测值4.2%、阴性预测值99.9%。

临床怎么用

  • SNP芯片结果提示罕见致病变异时,须经测序验证后方可用于临床决策。
  • 不应仅凭SNP芯片检测的罕见致病变异结果启动健康干预。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine whether the sensitivity and specificity of SNP chips are adequate for detecting rare pathogenic variants in a clinically unselected population. DESIGN: Retrospective, population based diagnostic evaluation. PARTICIPANTS: 49 908 people recruited to the UK Biobank with SNP chip and next generation sequencing data, and an additional 21 people who purchased consumer genetic tests and shared their data online via the Personal Genome Project. MAIN OUTCOME MEASURES: Genotyping (that is, identification of the correct DNA base at a specific genomic location) using SNP chips versus sequencing, with results split by frequency of that genotype in the population. Rare pathogenic variants in the BRCA1 and BRCA2 genes were selected as an exemplar for detailed analysis of clinically actionable variants in the UK Biobank, and BRCA related cancers (breast, ovarian, prostate, and pancreatic) were assessed in participants through use of cancer registry data. RESULTS: Overall, genotyping using SNP chips performed well compared with sequencing; sensitivity, specificity, positive predictive value, and negative predictive value were all above 99% for 108 574 common variants directly genotyped on the SNP chips and sequenced in the UK Biobank. However, the likelihood of a true positive result decreased dramatically with decreasing variant frequency; for variants that are very rare in the population, with a frequency below 0.001% in UK Biobank, the positive predictive value was very low and only 16% of 4757 heterozygous genotypes from the SNP chips were confirmed with sequencing data. Results were similar for SNP chip data from the Personal Genome Project, and 20/21 individuals analysed had at least one false positive rare pathogenic variant that had been incorrectly genotyped. For pathogenic variants in the BRCA1 and BRCA2 genes, which are individually very rare, the overall performance metrics for the SNP chips versus sequencing in the UK Biobank were: sensitivity 34.6%, specificity 98.3%, positive predictive value 4.2%, and negative predictive value 99.9%. Rates of BRCA related cancers in UK Biobank participants with a positive SNP chip result were similar to those for age matched controls (odds ratio 1.31, 95% confidence interval 0.99 to 1.71) because the vast majority of variants were false positives, whereas sequence positive participants had a significantly increased risk (odds ratio 4.05, 2.72 to 6.03). CONCLUSIONS: SNP chips are extremely unreliable for genotyping very rare pathogenic variants and should not be used to guide health decisions without validation.

来源:BMJ,查看原文。版权归原作者所有。

引用

  1. Mn W, L J, Jw H, et al. Use of SNP chips to detect rare pathogenic variants: retrospective, population based diagnostic evaluation. BMJ. 2021. PMID: 33589468. doi:10.1136/bmj.n214

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。